“Epilepsy is the most prevalent neurological disease and is characterised by recurrent seizures. Here we investigate: (i) the anticonvulsant profiles of cannabis-derived botanical drug substances (BDS) rich in cannabidivarin (CBDV) and containing cannabidiol (CBD) in acute in vivo seizure models and (ii) the binding of CBDV BDSs and their components at cannabinoid CB₁ receptors.

CDBV BDSs exerted significant anticonvulsant effects… 

CONCLUSIONS AND IMPLICATIONS:

CBDV BDSs exerted significant anticonvulsant effects in three models of seizure that were not mediated by the CB₁ cannabinoid receptor, and were of comparable efficacy to purified CBDV.

These findings strongly support the further clinical development of CBDV BDSs for treatment of epilepsy.”

http://www.ncbi.nlm.nih.gov/pubmed/23902406

“Cannabidivarin is anticonvulsant in mouse and rat… These results indicate that CBDV is an effective anticonvulsant in a broad range of seizure models.”  http://www.ncbi.nlm.nih.gov/pubmed/22970845